BUSINESS ACQUISITIONS AND DIVESTITURE - Narrative (Details)					1 Months Ended	3 Months Ended							6 Months Ended	9 Months Ended
	Oct. 02, 2017 USD ($)	May 25, 2017 USD ($)	Feb. 24, 2017 USD ($)	Feb. 23, 2017 USD ($)	Aug. 31, 2017 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Oct. 06, 2017 USD ($)
Business Acquisition [Line Items]
Amount drawn from loan														$ 50,000,000	$ 571,383,000
Cash received from working capital adjustment related to business acquisition														26,704,000
Payment for contingent consideration														15,900,000
Cost of good sold related to fair value inventory purchase accounting adjustments						$ 143,245,000				$ 101,757,000				425,032,000	287,340,000
Cash payment to former shareholders															225,552,000
Recognized loss on sale of short-term investment											$ 2,300,000			0	2,287,000
Change in fair value of contingent consideration														1,214,000	(2,773,000)
Net income						$ 13,295,000	$ 11,376,000	$ 10,992,000		$ 3,159,000	10,835,000	$ 6,394,000		$ 35,663,000	$ 20,388,000
BioD Morselized Amniotic Membrane Based Products | Product Concentration Risk
Business Acquisition [Line Items]
Percentage of revenue to product (less than)						1.00%				1.00%				1.00%	1.00%
Codman Specialty Surgical
Business Acquisition [Line Items]
Aggregate purchase price received																$ 46,400,000
Assets provided upon termination of transitional supply agreement liability						$ 1,300,000								$ 1,300,000
Codman Specialty Surgical | Disposal Group, Held-for-sale, Not Discontinued Operations
Business Acquisition [Line Items]
Pretax gain on sale of business, included in other income, net									$ 2,600,000
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition
Business Acquisition [Line Items]
Net income						2,400,000								14,400,000
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition | Derma Sciences
Business Acquisition [Line Items]
Net income				$ 2,900,000
Codman
Business Acquisition [Line Items]
Consideration for acquisition	$ 1,014,000,000
Revenue of acquired company						78,900,000								236,000,000
Purchase price adjustment						(800,000)							$ 3,200,000	3,964,000
Purchase price, working capital adjustments													6,200,000
Purchase price, inventory adjustments													$ 3,000,000
Purchase price, property, plant and equipment adjustment						5,500,000
Write off of construction in progress									6,300,000
Codman | Fair Value Adjustment to Inventory
Business Acquisition [Line Items]
Cost of good sold related to fair value inventory purchase accounting adjustments						2,800,000								17,300,000
Codman | Completed technology
Business Acquisition [Line Items]
Purchase price, intangible asset adjustment						4,700,000
Derma Sciences
Business Acquisition [Line Items]
Consideration for acquisition			$ 210,800,000
Payment of closing expenses			4,800,000
Settlement of stock compensation plan			4,300,000
Cash payment to former shareholders			201,700,000
Acquired deferred taxes			$ 14,524,000			14,500,000								14,500,000
Deferred tax asset, federal net operating loss						39,700,000								39,700,000
Deferred tax asset, intangibles						16,400,000								16,400,000
Deferred tax liabilities, intangibles						41,100,000								41,100,000
Deferred tax asset, various						500,000								500,000
Deferred tax liabilities, adjustment to estimated fair value											1,500,000
Deferred tax assets, adjustment to estimated fair value									3,300,000
Derma Sciences | BioD Earnout Payments
Business Acquisition [Line Items]
Payment for contingent consideration					$ 4,800,000	0
Revenue volatility percentage			13.50%
Contingent consideration maximum payout			$ 26,500,000
Estimated fair value of the remaining portion of the contingent consideration, liability			9,100,000						300,000
Derma Sciences | Product Payment Contingent Consideration
Business Acquisition [Line Items]
Contingent consideration maximum payout			29,700,000.0
Estimated fair value of the remaining portion of the contingent consideration, liability			$ 26,800,000
Product payment rate			98.00%
Change in fair value of contingent consideration											$ 900,000
Payment for the product payment		$ 26,600,000
Derma Sciences | Medihoney Earnout Payments
Business Acquisition [Line Items]
Payment for contingent consideration							$ 2,000,000
Revenue volatility percentage			27.50%
Contingent consideration maximum payout			$ 5,000,000.0
Estimated fair value of the remaining portion of the contingent consideration, liability			$ 1,400,000			$ 200,000			$ 1,400,000					$ 200,000
Derma Sciences | Measurement Input, Discount Rate | BioD Earnout Payments
Business Acquisition [Line Items]
Discounted cash flow model, measurement input			0.030
Derma Sciences | Measurement Input, Discount Rate | Product Payment Contingent Consideration
Business Acquisition [Line Items]
Discounted cash flow model, measurement input			0.025
Derma Sciences | Measurement Input, Discount Rate | Medihoney Earnout Payments
Business Acquisition [Line Items]
Discounted cash flow model, measurement input			0.045